The RON receptor tyrosine kinase: A key regulator of inflammation and cancer progression

Critical Reviews in Immunology

Volumn 33, Issue 6, 2013, Pages 549-574

  Wang, Xin ^a   Hankey, Pamela A ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Epithelial cell; Inflammation; Ron receptor tyrosine kinase

Indexed keywords

ARGINASE 1; BEVACIZUMAB; CBL PROTEIN; CETUXIMAB; CLAUDIN 3; CLAUDIN 4; COLLAGEN TYPE 4; ERLOTINIB; GAMMA INTERFERON; GEFITINIB; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; IMATINIB; INTERLEUKIN 12; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IMC 41A10; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C DELTA; PROTEIN P85; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; RON RECEPTOR TYROSINE KINASE; SORAFENIB; STAT1 PROTEIN; STAT3 PROTEIN; SUNITINIB; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADVANCED CANCER; APOPTOSIS; ARTICLE; BINDING SITE; BLADDER CANCER; BREAST CANCER; CANCER GROWTH; CANCER IMMUNOLOGY; CELL ADHESION; CELL DEATH; CELL GROWTH; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; CYTOKINE PRODUCTION; DOWN REGULATION; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IN VIVO STUDY; INFLAMMATION; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MACROPHAGE ACTIVATION; METASTASIS; NONHUMAN; OSTEOLYSIS; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKIN CANCER; THYROID CANCER; TISSUE REPAIR; TUMOR MICROENVIRONMENT; UPREGULATION; WOUND HEALING;

ANIMALS; CARCINOGENESIS; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; MACROPHAGE ACTIVATION; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84885225608     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevImmunol.2013007953     Document Type: Article

References (216)

1. Furge KA, Zhang YW, Vande Woude GF. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene. 2000;19:5582-5589.
2. Wang MH, Ronsin C, Gesnel MC, Coupey L, Skeel A, Leonard EJ, Breathnach R. Identifcation of the ron gene product as the receptor for the human macrophage stimulating protein. Science. 1994;266:117-119.
3. Ronsin C, Muscatelli F, Mattei MG, Breathnach R. A novel putative receptor protein tyrosine kinase of the met family. Oncogene. 1993;8:1195-1202.
4. Gaudino G, Follenzi A, Naldini L, Collesi C, Santoro M, Gallo KA, Godowski PJ, Comoglio PM. RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. EMBO J. 1994;13:3524-3532.
5. Leonard EJ, Danilkovitch A. Macrophage stimulating protein. Adv Cancer Res. 2000;77:139-167.
6. Skeel A, Yoshimura T, Showalter SD, Tanaka S, Appella E, Leonard EJ. Macrophage stimulating protein: purifcation, partial amino acid sequence, and cellular activity. J Exp Med. 1991;173:1227-1234.
7. Bezerra JA, Witte D P, Aronow BJ, Degen SJ. Hepatocyte-specifc expression of the mouse hepatocyte growth factor-like protein. Hepatology. 1993;18:394-399.
8. Wang MH, Yoshimura T, Skeel A, Leonard EJ. Proteolytic conversion of single chain precursor macrophage-stimulating protein to a biologically active heterodimer by contact enzymes of the coagulation cascade. J Biol Chem. 1994;269:3436-3440.
9. Yoshimura T, Yuhki N, Wang MH, Skeel A, Leonard EJ. Cloning, sequencing, and expression of human macrophage stimulating protein (MSP, MST1) confrms MSP as a member of the family of kringle proteins and locates the MSP gene on chromosome 3. J Biol Chem. 1993;268:15461-15468.
10. Leonard EJ. Biological aspects of macrophage-stimulating protein (MSP) and its receptor. Ciba Found Symp. 1997;212:183-191; discussion 92-97.
11. Angeloni D, Danilkovitch-Miagkova A, Miagkov A, Leonard EJ, Lerman MI. The soluble sema domain of the RON receptor inhibits macrophage-stimulating protein-induced receptor activation. J Biol Chem. 2004;279:3726-37232.
12. Collesi C, Santoro MM, Gaudino G, Comoglio PM. A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype. Mol Cell Biol. 1996;16:5518-5526.
13. Wang MH, Wang D, Chen YQ. Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase. Carcinogenesis. 2003;24:1291-1300.
14. Angeloni D, Danilkovitch-Miagkova A, Ivanov SV, Breathnach R, Johnson BE, Leonard EJ, Lerman MI. Gene structure of the human receptor tyrosine kinase RON and mutation analysis in lung cancer samples. Genes Chromosomes Cancer. 2000;29:147-156.
15. Correll PH, Paulson RF, Wei X. Molecular regulation of receptor tyrosine kinases in hematopoietic malignancies. Gene. 2006;374:26-38.
16. Huse M, Kuriyan J. The conformational plasticity of protein kinases. Cell. 2002;109:275-282.
17. Miller M, Leonard EJ. Mode of receptor binding and activation by plasminogen-related growth factors. FEBS Lett. 1998;429:1-3.
18. Chao KL, Tsai IW, Chen C, Herzberg O. Crystal structure of the Sema-PSI extracellular domain of human RON receptor tyrosine kinase. PLoS One. 2012;7:e41912.
19. Madhusudan, Trafny EA, Xuong NH, Adams JA, Ten Eyck LF, Taylor SS, Sowadski JM. cAMP- dependent protein kinase: crystallographic insights into substrate recognition and phosphotransfer. Protein Sci. 1994;3:176-187.
20. Wei X, Hao L, Ni S, Liu Q, Xu J, Correll P. Altered exon usage in the juxtamembrane domain of mouse and human Ron regulates receptor activity and signaling specifcity. J Biol Chem. 2005;280:40241-40251.
21. Wang J, Steinbacher S, Augustin M, Schreiner P, Epstein D, Mulvihill MJ, Crew A P. The crystal structure of a constitutively active mutant RON kinase suggests an intramolecular autophosphorylation hypothesis. Biochemistry. 2010;49:7972-7974.
22. Rickert KW, Patel SB, Allison TJ, Byrne NJ, Darke PL, Ford RE, Guerin DJ, Hall DL, Kornienko M, Lu J, Munshi SK, Reid JC, Shipman JM, Stanton EF, Wilson KJ, Young JR, Soisson SM, Lumb KJ. Structural basis for selective small molecule kinase inhibition of activated c-Met. Journal Biol Chem. 2011;286:11218-11225.
23. Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P, Giordano S, Graziani A, Panayotou G, Comoglio PM. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell. 1994;77:261-271.
24. Nguyen L, Holgado-Madruga M, Maroun C, Fixman ED, Kamikura D, Fournier T, Charest A, Tremblay ML, Wong AJ, Park M. Association of the multisubstrate docking protein Gab1 with the hepatocyte growth factor receptor requires a functional Grb2 binding site involving tyrosine 1356. J Biol Chem. 1997;272:20811-20819.
25. Bardelli A, Longati P, Gramaglia D, Stella MC, Comoglio PM. Gab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential. Oncogene. 1997;15:3103-3111.
26. Boccaccio C, Ando M, Tamagnone L, Bardelli A, Michieli P, Battistini C, Comoglio PM. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature. 1998;391:285-288.
27. Danilkovitch A, Skeel A, Leonard EJ. Macrophage stimulating protein-induced epithelial cell adhesion is mediated by a PI3-K-dependent, but FAK-independent mechanism. Exp Cell Res. 1999;248:575-582.
28. Li BQ, Wang MH, Kung HF, Ronsin C, Breathnach R, Leonard EJ, Kamata T. Macrophage-stimulating protein activates Ras by both activation and translocation of SOS nucleotide exchange factor. Biochem Biophys Res Commun. 1995;216:110-118.
29. Chen YQ, Zhou YQ, Angeloni D, Kurtz AL, Qiang XZ, Wang MH. Overexpression and activation of the RON receptor tyrosine kinase in a panel of human colorectal carcinoma cell lines. Exp Cell Res. 2000;261:229-238.
30. Danilkovitch-Miagkova A, Angeloni D, Skeel A, Donley S, Lerman M, Leonard EJ. Integrin-mediated RON growth factor receptor phosphorylation requires tyrosine kinase activity of both the receptor and c-Src. J Biol Chem. 2000;275:14783-14786.
31. Zhou YQ, Chen YQ, Fisher JH, Wang MH. Activation of the RON receptor tyrosine kinase by macrophage-stimulating protein inhibits inducible cyclooxygenase-2 expression in murine macrophages. J Biol Chem. 2002;277:38104-38110.
32. Camp ER, Liu W, Fan F, Yang A, Somcio R, Ellis LM. RON, a tyrosine kinase receptor involved in tumor progression and metastasis. Ann Surg Oncol. 2005;12:273-281.
33. Wang MH, Montero-Julian FA, Dauny I, Leonard EJ. Requirement of phosphatidylinositol-3 kinase for epithelial cell migration activated by human macrophage stimulating protein. Oncogene. 1996;13:2167-2175.
34. Schutzman JL, Borland CZ, Newman JC, Robinson MK, Kokel M, Stern MJ. The Caenorhabditis elegans EGL-15 signaling pathway implicates a DOS-like multisubstrate adaptor protein in fbroblast growth factor signal transduction. Mol Cell Biol. 2001;21:8104-8116.
35. Herbst R, Carroll PM, Allard JD, Schilling J, Raabe T, Simon MA. Daughter of sevenless is a substrate of the phosphotyrosine phosphatase Corkscrew and functions during sevenless signaling. Cell. 1996;85:899-909.
36. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577-580.
37. Finkelstein LD, Ney PA, Liu QP, Paulson RF, Correll PH. Sf-Stk kinase activity and the Grb2 binding site are required for Epo-independent growth of primary erythroblasts infected with Friend virus. Oncogene. 2002;21:3562-3570.
38. Lock LS, Frigault MM, Saucier C, Park M. Grb2-independent recruitment of Gab1 requires the C-terminal lobe and structural integrity of the Met receptor kinase domain. J Biol Chem. 2003;278:30083-30090.
39. Chaudhuri A, Xie MH, Yang B, Mahapatra K, Liu J, Marsters S, Bodepudi S, Ashkenazi A. Distinct involvement of the Gab1 and Grb2 adaptor proteins in signal transduction by the related receptor tyrosine kinases RON and MET. J Biol Chem. 2011;286:32762-32774.
40. Teal HE, Ni S, Xu J, Finkelstein LD, Cheng AM, Paulson RF, Feng GS, Correll PH. GRB2-mediated recruitment of GAB2, but not GAB1, to SF-STK supports the expansion of Friend virus-infected erythroid progenitor cells. Oncogene. 2006;25:2433-2443.
41. Feres KJ, Ischenko I, Hayman MJ. The RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells. Oncogene. 2009;28:279-288.
42. Park WS, Dong SM, Kim SY, Na EY, Shin MS, Pi JH, Kim BJ, Bae JH, Hong YK, Lee KS, Lee SH, Yoo NJ, Jang JJ, Pack S, Zhuang Z, Schmidt L, Zbar B, Lee JY. Somatic mutations in the kinase domain of the Met/ hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res. 1999;59:307-310.
43. Danilkovitch A, Leonard EJ. Kinases involved in MSP/ RON signaling. J Leukoc Biol. 1999;65:345-348.
44. Wei X, Ni S, Correll PH. Uncoupling ligand-dependent and -independent mechanisms for mitogen-activated protein kinase activation by the murine Ron receptor tyrosine kinase. J Biol Chem. 2005;280:35098-35107.
45. Santoro MM, Gaudino G, Marchisio PC. The MSP receptor regulates alpha6beta4 and alpha3beta1 integrins via 14-3-3 proteins in keratinocyte migration. Dev Cell. 2003;5:257-271.
46. Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I, Lavi S, Iwai K, Reiss Y, Ciechanover A, Lipkowitz S, Yarden Y. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell. 1999;4:1029-1040.
47. Joazeiro CA, Wing SS, Huang H, Leverson JD, Hunter T, Liu YC. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science. 1999;286:309-312.
48. Penengo L, Rubin C, Yarden Y, Gaudino G. c-Cbl is a critical modulator of the Ron tyrosine kinase receptor. Oncogene. 2003;22:3669-3679.
49. Peschard P, Fournier TM, Lamorte L, Naujokas MA, Band H, Langdon WY, Park M. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell. 2001;8:995-1004.
50. Iwama A, Okano K, Sudo T, Matsuda Y, Suda T. Molecular cloning of a novel receptor tyrosine kinase gene, STK, derived from enriched hematopoietic stem cells. Blood. 1994;83:3160-3169.
51. Quantin B, Schuhbaur B, Gesnel MC, Doll'e P, Breathnach R. Restricted expression of the ron gene encoding the macrophage stimulating protein receptor during mouse development. Dev Dyn. 1995;204:383-390.
52. Gaudino G, Avantaggiato V, Follenzi A, Acampora D, Simeone A, Comoglio PM. Te proto-oncogene RON is involved in development of epithelial, bone and neuro-endocrine tissues. Oncogene. 1995;11:2627-2637.
53. Wang MH, Lee W, Luo YL, Weis MT, Yao HP. Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells. J Pathol. 2007;213:402-411.
54. Brunelleschi S, Penengo L, Lavagno L, Santoro C, Colangelo D, Viano I, Gaudino G. Macrophage stimulating protein (MSP) evokes superoxide anion production by human macrophages of diferent origin. Br J Pharmacol. 2001;134:1285-1295.
55. Nanney LB, Skeel A, Luan J, Polis S, Richmond A, Wang MH, Leonard EJ. Proteolytic cleavage and activation of pro-macrophage-stimulating protein and upregulation of its receptor in tissue injury. J Invest Dermatol. 1998;111:573-581.
56. Iwama A, Wang MH, Yamaguchi N, Ohno N, Okano K, Sudo T, Takeya M, Gervais F, Morissette C, Leonard EJ, Suda T. Terminal diferentiation of murine resident peritoneal macrophages is characterized by expression of the STK protein tyrosine kinase, a receptor for macrophage-stimulating protein. Blood. 1995;86:3394-3403.
57. Ganesan R, Kolumam GA, Lin SJ, Xie MH, Santell L, Wu TD, Lazarus RA, Chaudhuri A, Kirchhofer D. Proteolytic activation of pro-macrophage-stimulating protein by hepsin. Mol Cancer Res. 2011;9:1175-1186.
58. Bhatt AS, Welm A, Farady CJ, Vasquez M, Wilson K, Craik CS. Coordinate expression and functional profling identify an extracellular proteolytic signaling pathway. Proc Natl Acad Sci U S A. 2007;104:5771-5776.
59. Kawaguchi M, Orikawa H, Baba T, Fukushima T, Kataoka H. Hepatocyte growth factor activator is a serum activator of single-chain precursor macrophage-stimulating protein. FEBS J. 2009;276:3481-3490.
60. Wang MH, Gonias SL, Skeel A, Wolf BB, Yoshimura T, Leonard EJ. Proteolytic activation of single-chain precursor macrophage-stimulating protein by nerve growth factor-gamma and epidermal growth factor-binding protein, members of the kallikrein family. J Biol Chem. 1994;269:13806-13810.
61. Wang MH, Skeel A, Leonard EJ. Proteolytic cleavage and activation of pro-macrophage-stimulating protein by resident peritoneal macrophage membrane proteases. J Clin Invest. 1996;97:720-727.
62. Skeel A, Leonard EJ. alpha 1-Antichymotrypsin is the human plasma inhibitor of macrophage ectoenzymes that cleave pro-macrophage stimulating protein. J Biol Chem. 2001;276:21932-21937.
63. Leonard EJ, Skeel A. Hepatic catabolism of intravenously administered pro-macrophage-stimulating protein in mice. J Leukoc Biol. 1996;60:453-458.
64. Rampino T, Collesi C, Gregorini M, Maggio M, Soccio G, Guallini P, Dal Canton A. Macrophage-stimulating protein is produced by tubular cells and activates mesangial cells. J Am Soc Nephrol. 2002;13:649-657.
65. Matsuzaki S, Canis M, Pouly JL, Dechelotte P, Okamura K, Mage G. The macrophage stimulating protein/ RON system: a potential novel target for prevention and treatment of endometriosis. Mol Hum Reprod. 2005;11:345-349.
66. Danilkovitch-Miagkova A, Leonard EJ. Anti-apoptotic action of macrophage stimulating protein (MSP). Apoptosis. 2001;6:183-190.
67. Comoglio PM, Tamagnone L, Boccaccio C. Plasminogen-related growth factor and semaphorin receptors: a gene superfamily controlling invasive growth. Exp Cell Res. 1999;253:88-99.
68. Birchmeier W, Brinkmann V, Niemann C, Meiners S, DiCesare S, Naundorf H, Sachs M. Role of HGF/ SF and c-Met in morphogenesis and metastasis of epithelial cells. Ciba Found Symp. 1997;212:230-240; discussion 40-6.
69. Pagan R, Sanchez A, Martin I, Llobera M, Fabregat I, Vilaro S. Efects of growth and diferentiation factors on the epithelial-mesenchymal transition in cultured neonatal rat hepatocytes. J Hepatol. 1999;31:895-904.
70. Cote M, Miller AD, Liu SL. Human RON receptor tyrosine kinase induces complete epithelial-to-mesenchymal transition but causes cellular senescence. Biochem Biophys Res Commun. 2007;360:219-225.
71. Danilkovitch A, Donley S, Skeel A, Leonard EJ. Two independent signaling pathways mediate the antiapoptotic action of macrophage-stimulating protein on epithelial cells. Mol Cell Biol. 2000;20:2218-2227.
72. Fassetta M, D'Alessandro L, Coltella N, Di Renzo MF, Rasola A. Hepatocyte growth factor installs a survival platform for colorectal cancer cell invasive growth and overcomes p38 MAPK-mediated apoptosis. Cell Signal. 2006;18:1967-1976.
73. Morrison AC, Correll PH. Activation of the stem cell-derived tyrosine kinase/RON receptor tyrosine kinase by macrophage-stimulating protein results in the induction of arginase activity in murine peritoneal macrophages. J Immunol. 2002;168:853-860.
74. Chen YQ, Fisher JH, Wang MH. Activation of the RON receptor tyrosine kinase inhibits inducible nitric oxide synthase (iNOS) expression by murine peritoneal exudate macrophages: phosphatidylinositol-3 kinase is required for RON-mediated inhibition of iNOS expression. J Immunol. 1998;161:4950-4959.
75. Waltz SE, Eaton L, Toney-Earley K, Hess KA, Peace BE, Ihlendorf JR, Wang MH, Kaestner KH, Degen SJ. Ron-mediated cytoplasmic signaling is dispensable for viability but is required to limit infammatory responses. J Clin Invest. 2001;108:567-576.
76. Forgie A, Wyatt S, Correll PH, Davies AM. Macrophage stimulating protein is a target-derived neurotrophic factor for developing sensory and sympathetic neurons. Development. 2003;130:995-1002.
77. Boyer B, Valles AM, Edme N. Induction and regulation of epithelial-mesenchymal transitions. Biochem Pharmacol. 2000;60:1091-1099.
78. Cereijido M, Shoshani L, Contreras RG. Molecular physiology and pathophysiology of tight junctions. I. Biogenesis of tight junctions and epithelial polarity. Am J Physiol Gastrointest Liver Physiol. 2000;279:G477-G482.
79. Danilkovitch-Miagkova A, Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest. 2002;109:863-867.
80. Bardelli A, Pugliese L, Comoglio PM. "Invasive-growth" signaling by the Met/HGF receptor: the hereditary renal carcinoma connection. Biochim Biophys Acta. 1997;1333:M41-M51.
81. Santoro MM, Collesi C, Grisendi S, Gaudino G, Comoglio PM. Constitutive activation of the RON gene promotes invasive growth but not transformation. Mol Cell Biol. 1996;16:7072-7083.
82. Lutz MA, Correll PH. Activation of CR3-mediated phagocytosis by MSP requires the RON receptor, tyrosine kinase activity, phosphatidylinositol 3-kinase, and protein kinase C zeta. J Leukoc Biol. 2003;73:802-814.
83. Mera A, Suga M, Nakayama Y, Ando M, Suda T, Yamaguchi N. Redistribution of ERK/MAP kinase to uropod-like structures in interleukin-3-induced cell shape changes. Immunol Lett. 2002;84:117-124.
84. Mera A, Suga M, Ando M, Suda T, Yamaguchi N. Induction of cell shape changes through activation of the interleukin-3 common beta chain receptor by the RON receptor-type tyrosine kinase. J Biol Chem. 1999;274:15766-15774.
85. Klatt A, Zhang Z, Kalantari P, Hankey PA, Gilmour DS, Henderson AJ. Te receptor tyrosine kinase RON represses HIV-1 transcription by targeting RNA polymerase II processivity. J Immunol. 2008;180:1670-1677.
86. Hay ED. Role of cell-matrix contacts in cell migration and epithelial-mesenchymal transformation. Cell Difer Dev. 1990;32:367-375.
87. Sheppard D. Epithelial integrins. Bioessays. 1996;18:655-660.
88. Danilkovitch-Miagkova A, Leonard EJ. Crosstalk between RON receptor tyrosine kinase and other transmembrane receptors. Histol Histopathol. 2001;16:623-631.
89. Savagner P. Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays. 2001;23:912-923.
90. Lamorte L, Royal I, Naujokas M, Park M. Crk adapter proteins promote an epithelial-mesenchymal-like transition and are required for HGF-mediated cell spreading and breakdown of epithelial adherens junctions. Mol Biol Cell. 2002;13:1449-1461.
91. Piek E, Moustakas A, Kurisaki A, Heldin CH, ten Dijke P. TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdiferentiation in NMuMG breast epithelial cells. J Cell Sci. 1999;112(Pt 24):4557-4568.
92. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, Arteaga CL, Moses HL. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdiferentiation through a RhoA-dependent mechanism. Mol Biol Cell. 2001;12:27-36.
93. Miyazono K. TGF-beta signaling by Smad proteins. Cytokine Growth Factor Rev. 2000;11:15-22.
94. Follenzi A, Bakovic S, Gual P, Stella MC, Longati P, Comoglio PM. Cross-talk between the proto-oncogenes Met and Ron. Oncogene. 2000;19:3041-3049.
95. Cowin AJ, Kallincos N, Hatzirodos N, Robertson JG, Pickering KJ, Couper J, Belford DA. Hepatocyte growth factor and macrophage-stimulating protein are upregulated during excisional wound repair in rats. Cell Tissue Res. 2001;306:239-250.
96. Morrison AC, Wilson CB, Ray M, Correll PH. Macrophage-stimulating protein, the ligand for the stem cell-derived tyrosine kinase/RON receptor tyrosine kinase, inhibits IL-12 production by primary peritoneal macrophages stimulated with IFN-gamma and lipopolysaccharide. J Immunol. 2004;172:1825-1832.
97. Leonard EJ, Skeel AH. Enhancement of spreading, phagocytosis and chemotaxis by macrophage stimulating protein (MSP). Adv Exp Med Biol. 1979;121B:181-194.
98. Suzuki Y, Funakoshi H, Machide M, Matsumoto K, Nakamura T. Regulation of cell migration and cytokine production by HGF-like protein (HLP)/macrophage stimulating protein (MSP) in primary microglia. Biomed Res. 2008;29:77-84.
99. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci. 2008;13:453-461.
100. Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3:23-35.
101. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011;11:723-737.
102. Murray PJ, Wynn TA. Obstacles and opportunities for understanding macrophage polarization. J Leukoc Biol. 2011;89:557-563.
103. Odegaard JI, Chawla A. Alternative macrophage activation and metabolism. Annu Rev Pathol. 2011;6:275-297.
104. Goerdt S, Politz O, Schledzewski K, Birk R, Gratchev A, Guillot P, Hakiy N, Klemke CD, Dippel E, Kodelja V, Orfanos CE. Alternative versus classical activation of macrophages. Pathobiology. 1999;67:222-226.
105. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8:958-969.
106. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol. 2009;27:451-483.
107. Munder M, Eichmann K, Moran JM, Centeno F, Soler G, Modolell M. T1/T2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J Immunol. 1999;163:3771-3777.
108. Modolell M, Corraliza IM, Link F, Soler G, Eichmann K. Reciprocal regulation of the nitric oxide synthase/ arginase balance in mouse bone marrow-derived macrophages by TH1 and TH2 cytokines. Eur J Immunol. 1995;25:1101-1104.
109. Hesse M, Modolell M, La Flamme AC, Schito M, Fuentes JM, Cheever AW, Pearce EJ, Wynn TA. Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism. J Immunol. 2001;167:6533-6544.
110. Teupser D, Burkhardt R, Wilfert W, Hafner I, Nebendahl K, Tiery J. Identifcation of macrophage arginase I as a new candidate gene of atherosclerosis resistance. Arterioscler Tromb Vasc Biol. 2006;26:365-371.
111. Tomas AC, Sala-Newby GB, Ismail Y, Johnson JL, Pasterkamp G, Newby AC. Genomics of foam cells and nonfoamy macrophages from rabbits identifes arginase-I as a diferential regulator of nitric oxide production. Arterioscler Tromb Vasc Biol. 2007;27:571-577.
112. El Kasmi KC, Qualls JE, Pesce J T, Smith AM, Tompson RW, Henao-Tamayo M, Basaraba RJ, Konig T, Schleicher U, Koo MS, Kaplan G, Fitzgerald KA, Tuomanen EI, Orme IM, Kanneganti TD, Bogdan C, Wynn TA, Murray PJ. Toll-like receptor-induced arginase 1 in macrophages thwarts efective immunity against intracellular pathogens. Nat Immunol. 2008;9:1399-1406.
113. Bhatt AS, Welm A, Farady CJ, Vasquez M, Wilson K, Craik CS. Coordinate expression and functional profling identify an extracellular proteolytic signaling pathway. Proc Natl Acad Sci U S A. 2007;104:5771-5776.
114. Correll PH, Iwama A, Tondat S, Mayrhofer G, Suda T, Bernstein A. Deregulated infammatory response in mice lacking the STK/RON receptor tyrosine kinase. Genes Funct. 1997;1:69-83.
115. Correll PH, Morrison AC, Lutz MA. Receptor tyrosine kinases and the regulation of macrophage activation. J Leukoc Biol. 2004;75:731-737.
116. Sharda DR, Yu S, Ray M, Squadrito ML, De Palma M, Wynn TA, Morris SM Jr, Hankey PA. Regulation of macrophage arginase expression and tumor growth by the Ron receptor tyrosine kinase. J Immunol. 2011;187:2181-2192.
117. Liu Q P, Fruit K, Ward J, Correll PH. Negative regulation of macrophage activation in response to IFN-gamma and lipopolysaccharide by the STK/RON receptor tyrosine kinase. J Immunol. 1999;163:6606-6613.
118. Ray M, Yu S, Sharda DR, Wilson CB, Liu Q, Kaushal N, Prabhu KS, Hankey PA. Inhibition of TLR4-induced IkappaB kinase activity by the RON receptor tyrosine kinase and its ligand, macrophage-stimulating protein. J Immunol. 2010;185:7309-7316.
119. Yuk JM, Shin DM, Lee HM, Kim JJ, Kim SW, Jin HS, Yang CS, Park KA, Chanda D, Kim DK, Huang SM, Lee SK, Lee CH, Kim JM, Song CH, Lee SY, Hur GM, Moore DD, Choi HS, Jo EK. The orphan nuclear receptor SHP acts as a negative regulator in infammatory signaling triggered by Toll-like receptors. Nat Immunol. 2011;12:742-751.
120. Lutz MA, Gervais F, Bernstein A, Hattel AL, Correll PH. STK receptor tyrosine kinase regulates susceptibility to infection with Listeria monocytogenes. Infect Immun. 2002;70:416-418.
121. Nikolaidis NM, Gray JK, Gurusamy D, Fox W, Stuart WD, Huber N, Waltz SE. Ron receptor tyrosine kinase negatively regulates TNFalpha production in alveolar macrophages by inhibiting NF-kappaB activity and Adam17 production. Shock. 2010;33:197-204.
122. Wilson CB, Ray M, Lutz M, Sharda D, Xu J, Hankey PA. The RON receptor tyrosine kinase regulates IFN-gamma production and responses in innate immunity. J Immunol. 2008;181:2303-2310.
123. Gardner CR, Hankey P, Mishin V, Francis M, Yu S, Laskin JD, Laskin DL. Regulation of alternative macrophage activation in the liver following acetaminophen intoxication by stem cell-derived tyrosine kinase. Toxicol Appl Pharmacol. 2012;262:139-148.
124. Nikolaidis NM, Kulkarni RM, Gray JK, Collins MH, Waltz SE. Ron receptor defcient alveolar myeloid cells exacerbate LPS-induced acute lung injury in the murine lung. Innate Immun. 2011;17:499-507.
125. Lentsch AB, Pathrose P, Kader S, Kuboki S, Collins MH, Waltz SE. The Ron receptor tyrosine kinase regulates acute lung injury and suppresses nuclear factor kappaB activation. Shock. 2007;27:274-280.
126. Beckly JB, Hancock L, Geremia A, Cummings JR, Morris A, Cooney R, Pathan S, Guo C, Jewell DP. Two-stage candidate gene study of chromosome 3p demonstrates an association between nonsynonymous variants in the MST1R gene and Crohn's disease. Infamm Bowel Dis. 2008;14:500-507.
127. Goyette P, Lefebvre C, Ng A, Brant SR, Cho JH, Duerr RH, Silverberg MS, Taylor KD, Latiano A, Aumais G, Deslandres C, Jobin G, Annese V, Daly MJ, Xavier RJ, Rioux JD. Gene-centric association mapping of chromosome 3p implicates MST1 in IBD pathogenesis. Mucosal Immunol. 2008;1:131-138.
128. Giulian D, Vaca K, Noonan CA. Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1. Science. 1990;250:1593-1596.
129. Gartner S, Markovits P, Markovitz DM, Kaplan MH, Gallo RC, Popovic M. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science. 1986;233:215-219.
130. Lee ES, Kalantari P, Tsutsui Section S, Klatt A, Holden J, Correll PH, Power Section C, Henderson AJ. RON receptor tyrosine kinase, a negative regulator of inflammation, inhibits HIV-1 transcription in monocytes/ macrophages and is decreased in brain tissue from patients with AIDS. J Immunol. 2004;173:6864-6872.
131. Kalantari P, Harandi OF, Hankey PA, Henderson AJ. HIV-1 Tat mediates degradation of RON receptor tyrosine kinase, a regulator of inflammation. J Immunol. 2008;181:1548-1555.
132. Lamorte L, Park M. The receptor tyrosine kinases: role in cancer progression. Surg Oncol Clin N Am. 2001;10:271-288, viii.
133. Bennasroune A, Gardin A, Aunis D, Cremel G, Hubert P. Tyrosine kinase receptors as attractive targets of cancer therapy. Crit Rev Oncol Hematol. 2004;50:23-38.
134. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411:355-365.
135. Senchenko VN, Liu J, Loginov W, Bazov I, Angeloni D, Seryogin Y, Ermilova V, Kazubskaya T, Garkavtseva R, Zabarovska VI, Kashuba VI, Kisselev LL, Minna JD, Lerman MI, Klein G, Braga EA, Zabarovsky ER. Discovery of frequent homozygous deletions in chromosome 3p21.3 LUCA and AP20 regions in renal, lung and breast carcinomas. Oncogene. 2004;23:5719-5728.
136. Welm AL, Sneddon JB, Taylor C, Nuyten DS, van de Vijver MJ, Hasegawa BH, Bishop JM. The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proc Natl Acad Sci U S A. 2007;104:7570-7575.
137. Wang MH, Dlugosz AA, Sun Y, Suda T, Skeel A, Leonard EJ. Macrophage-stimulating protein induces proliferation and migration of murine keratinocytes. Exp Cell Res. 1996;226:39-46.
138. Sakamoto O, Iwama A, Amitani R, Takehara T, Yamaguchi N, Yamamoto T, Masuyama K, Yamanaka T, Ando M, Suda T. Role of macrophage-stimulating protein and its receptor, RON tyrosine kinase, in ciliary motility. J Clin Invest. 1997;99:701-709.
139. Maggiora P, Marchio S, Stella MC, Giai M, Belfore A, De Bortoli M, Di Renzo MF, Costantino A, Sismondi P, Comoglio PM. Overexpression of the RON gene in human breast carcinoma. Oncogene. 1998;16:2927-2933.
140. Zinser GM, Leonis MA, Toney K, Pathrose P, Tobe M, Kader SA, Peace BE, Beauman SR, Collins MH, Waltz SE. Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-catenin activation. Cancer Res. 2006;66:11967-11974.
141. Wang MH, Kurtz AL, Chen Y. Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells. Carcinogenesis. 2000;21:1507-1512.
142. Zhou YQ, He C, Chen YQ, Wang D, Wang MH. Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of diferent splicing RON variants and their oncogenic potential. Oncogene. 2003;22:186-197.
143. Chen YQ, Zhou YQ, Fu LH, Wang D, Wang MH. Multiple pulmonary adenomas in the lung of transgenic mice overexpressing the RON receptor tyrosine kinase. Recepteur d'origine nantais. Carcinogenesis. 2002;23:1811-1819.
144. Chen YQ, Zhou YQ, Fisher JH, Wang MH. Targeted expression of the receptor tyrosine kinase RON in distal lung epithelial cells results in multiple tumor formation: oncogenic potential of RON in vivo. Oncogene. 2002;21:6382-6386.
145. Barkley JE, Green MR. Bronchioloalveolar carcinoma. J Clin Oncol. 1996;14:2377-2386.
146. Willett CG, Wang MH, Emanuel RL, Graham SA, Smith DI, Shridhar V, Sugarbaker DJ, Sunday ME. Macrophage-stimulating protein and its receptor in non-small-cell lung tumors: induction of receptor tyrosine phosphorylation and cell migration. Am J Respir Cell Mol Biol. 1998;18:489-496.
147. Tomas RM, Toney K, Fenoglio-Preiser C, Revelo-Penafel MP, Hingorani SR, Tuveson DA, Waltz SE, Lowy AM. The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res. 2007;67:6075-6082.
148. Camp ER, Yang A, Gray MJ, Fan F, Hamilton SR, Evans DB, Hooper AT, Pereira DS, Hicklin DJ, Ellis LM. Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target. Cancer. 2007;109:1030-1039.
149. Jaquish DV, Yu P T, Shields DJ, French RP, Maruyama KP, Niessen S, Hoover H, A Cheresh D, Cravatt B, Lowy AM. IGF1-R signals through the RON receptor to mediate pancreatic cancer cell migration. Carcinogenesis. 2011;32:1151-1156.
150. Cheng HL, Liu HS, Lin YJ, Chen HH, Hsu PY, Chang TY, Ho CL, Tzai TS, Chow NH. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. Br J Cancer. 2005;92:1906-1914.
151. Hsu PY, Liu HS, Cheng HL, Tzai TS, Guo HR, Ho CL, Chow NH. Collaboration of RON and epidermal growth factor receptor in human bladder carcinogenesis. J Urol. 2006;176:2262-2267.
152. Leonis MA, Tobe MN, Waltz SE. Ron-receptor tyrosine kinase in tumorigenesis and metastasis. Future Oncol. 2007;3:441-448.
153. Fracchioli S, Katsaros D, Maggiora P, Di Renzo MF, Massobrio M. Evaluation of Ron and Met proto-oncogene expression in epithelial ovarian tumors. Minerva Ginecol. 1999;51:359-364.
154. Maggiora P, Lorenzato A, Fracchioli S, Costa B, Castagnaro M, Arisio R, Katsaros D, Massobrio M, Comoglio PM, Flavia Di Renzo M. The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Experimental cell research. 2003;288:382-389.
155. O'Toole JM, Rabenau KE, Burns K, Lu D, Mangalampalli V, Balderes P, Covino N, Bassi R, Prewett M, Gottfredsen KJ, Tobe MN, Cheng Y, Li Y, Hicklin DJ, Zhu Z, Waltz SE, Hayman MJ, Ludwig DL, Pereira DS. Terapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res. 2006;66:9162-9170.
156. Tobe MN, Gurusamy D, Pathrose P, Waltz SE. The Ron receptor tyrosine kinase positively regulates angiogenic chemokine production in prostate cancer cells. Oncogene. 2010;29:214-226.
157. Lee WY, Chen HH, Chow NH, Su WC, Lin PW, Guo HR. Prognostic signifcance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin Cancer Res. 2005;11:2222-2228.
158. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Tun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
159. Wang D, Shen Q, Chen YQ, Wang MH. Collaborative activities of macrophage-stimulating protein and transforming growth factor-beta1 in induction of epithelial to mesenchymal transition: roles of the RON receptor tyrosine kinase. Oncogene. 2004;23:1668-1680.
160. Ishizawar R, Parsons SJ. c-Src and cooperating partners in human cancer. Cancer Cell. 2004;6:209-214.
161. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, Chin L, DePinho RA. Coactivation of receptor tyrosine kinases afects the response of tumor cells to targeted therapies. Science. 2007;318:287-290.
162. Peace BE, Toney-Earley K, Collins MH, Waltz SE. Ron receptor signaling augments mammary tumor formation and metastasis in a murine model of breast cancer. Cancer Res. 2005;65:1285-1293.
163. Zhao H, Chen MS, Lo YH, Waltz SE, Wang J, Ho PC, Vasiliauskas J, Plattner R, Wang YL, Wang SC. The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancer. Oncogene. 2013 Apr 1. [Epub ahead of print]
164. Zhao H, Ho PC, Lo YH, Espejo A, Bedford MT, Hung MC, Wang SC. Interaction of proliferation cell nuclear antigen (PCNA) with c-Abl in cell proliferation and response to DNA damages in breast cancer. PLoS One. 2012;7:e29416.
165. Wang SC, Nakajima Y, Yu YL, Xia W, Chen CT, Yang CC, McIntush EW, Li LY, Hawke DH, Kobayashi R, Hung MC. Tyrosine phosphorylation controls PCNA function through protein stability. Nat Cell Biol. 2006;8:1359-1368.
166. Srinivasan D, Plattner R. Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells. Cancer Res. 2006;66:5648-5655.
167. Srinivasan D, Sims J T, Plattner R. Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival. Oncogene. 2008;27:1095-1105.
168. Lin J, Arlinghaus R. Activated c-Abl tyrosine kinase in malignant solid tumors. Oncogene. 2008;27:4385-4391.
169. Srinivasan D, Kaetzel DM, Plattner R. Reciprocal regulation of Abl and receptor tyrosine kinases. Cell Signal. 2009;21:1143-1150.
170. Tanos B, Pendergast AM. Abl tyrosine kinase regulates endocytosis of the epidermal growth factor receptor. J Biol Chem. 2006;281:32714-32723.
171. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003;21:2787-2799.
172. Jonkers J, Derksen PW. Modeling metastatic breast cancer in mice. J Mammary Gland Biol Neoplasia. 2007;12:191-203.
173. Xu XM, Zhou YQ, Wang MH. Mechanisms of cytoplasmic {beta}-catenin accumulation and its involvement in tumorigenic activities mediated by oncogenic splicing variant of the receptor originated from Nantes tyrosine kinase. J Biol Chem. 2005;280:25087-25094.
174. Xu XM, Wang D, Shen Q, Chen YQ, Wang MH. RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells. Oncogene. 2004;23:8464-8474.
175. Lu Y, Yao H P, Wang MH. Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets. Cancer Lett. 2007;257:157-164.
176. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
177. Tobe MN, Gray JK, Gurusamy D, Paluch AM, Wagh PK, Pathrose P, Lentsch AB, Waltz SE. Te Ron receptor promotes prostate tumor growth in the TRAMP mouse model. Oncogene. 2011;30:4990-4998.
178. Gray JK, Paluch AM, Stuart WD, Waltz SE. Ron receptor overexpression in the murine prostate induces prostate intraepithelial neoplasia. Cancer Lett. 2012;314:92-101.
179. Jiang WG, Ye L, Ablin RJ, Kynaston HG, Mason MD. The prostate transglutaminase, TGase-4, coordinates with the HGFL/MSP-RON system in stimulating the migration of prostate cancer cells. Int J Oncol. 2010;37:413-418.
180. Palmarini M, Fan H. Retrovirus-induced ovine pulmonary adenocarcinoma, an animal model for lung cancer. J Natl Cancer Inst. 2001;93:1603-1614.
181. Danilkovitch-Miagkova A, Duh FM, Kuzmin I, Angeloni D, Liu SL, Miller AD, Lerman MI. Hyaluronidase 2 negatively regulates RON receptor tyrosine kinase and mediates transformation of epithelial cells by jaagsiekte sheep retrovirus. Proc Natl Acad Sci U S A. 2003;100:4580-4585.
182. Teal HE, Craici A, Paulson RF, Correll PH. Macrophage-stimulating protein cooperates with erythropoietin to induce colony formation and MAP kinase activation in primary erythroid progenitor cells. J Hematother Stem Cell Res. 2003;12:165-177.
183. van den Akker E, van Dijk T, Parren-van Amelsvoort M, Grossmann KS, Schaeper U, Toney-Earley K, Waltz SE, Lowenberg B, von Lindern M. Tyrosine kinase receptor RON functions downstream of the erythropoietin receptor to induce expansion of erythroid progenitors. Blood. 2004;103:4457-4465.
184. Persons DA, Paulson RF, Loyd MR, Herley MT, Bodner SM, Bernstein A, Correll PH, Ney PA. Fv2 encodes a truncated form of the Stk receptor tyrosine kinase. Nat Genet. 1999;23:159-165.
185. Reilly J T. Receptor tyrosine kinases in normal and malignant haematopoiesis. Blood Rev. 2003;17:241-248.
186. He S, Ni S, Hegde S, Wang X, Sharda DR, August A, Paulson RF, Hankey PA. Activation of the N-terminally truncated form of the Stk receptor tyrosine kinase Sf-Stk by Friend virus-encoded gp55 is mediated by cysteine residues in the ecotropic domain of gp55 and the extracellular domain of Sf-Stk. J Virol. 2010;84:2223-2235.
187. Hegde S, Ni S, He S, Yoon D, Feng GS, Watowich SS, Paulson RF, Hankey PA. Stat3 promotes the development of erythroleukemia by inducing Pu.1 expression and inhibiting erythroid diferentiation. Oncogene. 2009;28:3349-3359.
188. Ni S, Zhao C, Feng GS, Paulson RF, Correll PH. A novel Stat3 binding motif in Gab2 mediates transformation of primary hematopoietic cells by the Stk/Ron receptor tyrosine kinase in response to Friend virus infection. Mol Cell Biol. 2007;27:3708-3715.
189. Fialin C, Larrue C, Vergez F, Sarry JE, Bertoli S, Mansat-De Mas V, Demur C, Delabesse E, Payrastre B, Manenti S, Roche S, Recher C. The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors. Leukemia. 2013;27:325-335.
190. Bardella C, Costa B, Maggiora P, Patane S, Olivero M, Ranzani GN, De Bortoli M, Comoglio PM, Di Renzo MF. Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression. Cancer Res. 2004;64:5154-5161.
191. Liu X, Zhao L, Derose YS, Lin YC, Bieniasz M, Eyob H, Buys SS, Neumayer L, Welm AL. Short-form Ron Promotes spontaneous breast cancer metastasis through interaction with phosphoinositide 3-kinase. Genes Cancer. 2011;2:753-762.
192. Wetzel CC, Leonis MA, Dent A, Olson MA, Longmeier AM, Ney PA, Boivin GP, Kader SA, Caldwell CC, Degen SJ, Waltz SE. Short-form Ron receptor is required for normal IFN-gamma production in concanavalin A-induced acute liver injury. Am J Physiol Gastrointest Liver Physiol. 2007;292:G253-G261.
193. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, Rimoldi M, Biswas SK, Allavena P, Mantovani A. Macrophage polarization in tumour progression. Semin Cancer Biol. 2008;18:349-355.
194. Kretschmann KL, Eyob H, Buys SS, Welm AL. The macrophage stimulating protein/Ron pathway as a potential therapeutic target to impede multiple mechanisms involved in breast cancer progression. Curr Drug Targets. 2010;11:1157-1168.
195. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4:71-78.
196. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002;196:254-265.
197. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized infammation in the initiation and promotion of malignant disease. Cancer Cell. 2005;7:211-217.
198. Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, Delgado A, Correa P, Brayer J, Sotomayor EM, Antonia S, Ochoa JB, Ochoa AC. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 2004;64:5839-5849.
199. Gurusamy D, Gray JK, Pathrose P, Kulkarni RM, Finkleman FD, Waltz SE. Myeloid-specifc expression of Ron receptor kinase promotes prostate tumor growth. Cancer Res. 2013;73:1752-1763.
200. Wynn TA, Barron L. Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis. 2010;30:245-257.
201. Eyob H, Ekiz HA, Derose YS, Waltz SE, Williams MA, Welm AL. Inhibition of Ron kinase blocks conversion of micrometastases to overt metastases by boosting anti-tumor immunity. Cancer Discov. 2013;3:751-760.
202. Coleman R, Gnant M. New results from the use of bisphosphonates in cancer patients. Curr Opin Support Palliat Care. 2009;3:213-218.
203. Kozlow W, Guise TA. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia. 2005;10:169-180.
204. Chen YC, Sosnoski DM, Mastro AM. Breast cancer metastasis to the bone: mechanisms of bone loss. Breast Cancer Res. 2010;12:215.
205. Kurihara N, Tatsumi J, Arai F, Iwama A, Suda T. Macrophage-stimulating protein (MSP) and its receptor, RON, stimulate human osteoclast activity but not proliferation: efect of MSP distinct from that of hepatocyte growth factor. Exp Hematol. 1998;26:1080-1085.
206. Ferrara N. VEGF as a therapeutic target in cancer. Oncology. 2005;69(Suppl 3):11-6.
207. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6:443-446.
208. Ben-Kasus T, Schechter B, Sela M, Yarden Y. Cancer therapeutic antibodies come of age: targeting minimal residual disease. Mol Oncol. 2007;1:42-54.
209. Casaletto JB, McClatchey AI. Spatial regulation of receptor tyrosine kinases in development and cancer. Nat Rev Cancer. 2012;12:387-400.
210. Angeloni D, Danilkovitch-Miagkova A, Ivanova T, Braga E, Zabarovsky E, Lerman MI. Hypermethylation of Ron proximal promoter associates with lack of full-length Ron and transcription of oncogenic short-Ron from an internal promoter. Oncogene. 2007;26:4499-4512.
211. Wang MH, Lao WF, Wang D, Luo YL, Yao HP. Blocking tumorigenic activities of colorectal cancer cells by a splicing RON receptor variant defective in the tyrosine kinase domain. Cancer Biol Ter. 2007;6:1121-1129.
212. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249-257.
213. Zhang Y, Kaplan-Lefko PJ, Rex K, Yang Y, Moriguchi J, Osgood T, Mattson B, Coxon A, Reese M, Kim TS, Lin J, Chen A, Burgess TL, Dussault I. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo. Cancer Res. 2008;68:6680-6687.
214. Schroeder GM, An Y, Cai ZW, Chen XT, Clark C, Cornelius LA, Dai J, Gullo-Brown J, Gupta A, Henley B, Hunt J T, Jeyaseelan R, Kamath A, Kim K, Lippy J, Lombardo LJ, Manne V, Oppenheimer S, Sack JS, Schmidt RJ, Shen G, Stefanski K, Tokarski JS, Trainor GL, Wautlet BS, Wei D, Williams DK, Zhang Y, Fargnoli J, Borzilleri RM. Discovery of N-(4- (2-amino-3-chloropyridin-4-yloxy)-3-fuorophenyl)-4- ethoxy-1-(4-fuorophenyl)-2-oxo-1,2-dihydropyridine- 3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. J Med Chem. 2009;52:1251-1254. http://www.visir.is/vidbuid-ad-farlagafrumvarp-taki- breytingum/article/2013131009673
215. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 2003;22:309-325.
216. Raeppel S, Gaudette F, Mannion M, Claridge S, Saavedra O, Isakovic L, Deziel R, Beaulieu N, Beaulieu C, Dupont I, Nguyen H, Wang J, Macleod AR, Maroun C, Besterman JM, Vaisburg A. Identification of a novel series of potent RON receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2010;20:2745-2749.